Guillermina (Gigi) Lozano, Ph.D.
Department of Genetics, Division of Discovery Science
About Dr. Guillermina (Gigi) Lozano
Guillermina (Gigi) Lozano is a renowned geneticist recognized for her studies of the p53 tumor suppressor pathway. This pathway is undermined in a large percent of human cancers via mutations and deletions of p53. Her laboratory identified a transcriptional activation function for p53. Using mouse models, her team characterized the physiological importance of Mdm2 and Mdm4 proteins as potent inhibitors of p53. The Mdm proteins are over expressed in many cancers that lack p53 mutations presenting an alternate mechanism of eliminating p53 activity. Other mouse models inheriting the most common p53 mutations revealed gain-of-function phenotypes that drive metastases.
Dr. Lozano received her BS degree in Biology and Mathematics, Magna Cum Laude, at the University of Texas Rio Grande Valley. She completed graduate studies at Rutgers University and the University of Medicine and Dentistry of New Jersey, and a post-doctoral fellowship with Dr. Arnold Levine at Princeton University.
Dr. Lozano was hired as an Instructor at The University of Texas MD Anderson Cancer Center in 1987 and quickly rose through the ranks to her current position as professor and chair of the department of Genetics. Dr. Lozano is a member of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences. She has received the Minorities in Cancer Research Jane Cooke Wright Lectureship and the Women in Cancer Research Charlotte Friend Lectureship awards both from the American Association for Cancer Research. She is also the recipient of distinguished alumni awards from both her undergraduate and graduate alma maters.
View a complete list of Dr. Lozano's publications.
Visit Dr. Lozano's Lab website.
Follow Dr. Lozano on Twitter: @drgglozano
Present Title & Affiliation
Primary Appointment
Endowed Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer, Division of Discovery Science, Department of Genetics, Houston, TX
Chair, Department of Genetics, Houston, TX
Professor, Department of Genetics, Houston, Texas
Faculty Member, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX
Research Interests
- p53 pathway
- tumor suppressors
- mouse models
Mutation of the p53 gene is a critical event in the elaboration of many tumors of diverse origin. The p53 protein is activated in response to DNA damage, serving as a checkpoint in the elimination or repair of cells with damaged DNA. Alterations in components of the p53 pathway, such as amplification of the Mdm2 gene, which encodes a p53 inhibitor, also contribute to tumorigenesis. The overall goal of my laboratory is to understand the signals that regulate the p53 pathway and the consequences of expressing wild-type or mutant p53. Toward this goal, we are generating mouse models to address the importance of various p53 mutations in tumor development in vivo. The first mice generated were those expressing a common p53 mutation identified in human cancers. Mice expressing the p53R172H mutant develop osteosarcomas and carcinomas that metastasized at very high frequency. This study also indicates that mutant p53 is inherently unstable in vivo suggesting that other genetic alterations in tumor cells stabilize p53. We have generated mice with another interesting mutant that distinguishes the ability of p53 to induce apoptosis or cell cycle arrest. The p53R172P mutant cannot transactivate genes that induce apoptosis yet retains the ability to induce the p21 gene involved in cell cycle arrest. Importantly, this mutant shows delayed tumorigenesis suggesting that p53 activities other than apoptosis are also critical for tumor suppression. Tumors that arise in these mice are also genomically stable suggesting that the p53R172P mutant transactivates genes involved in maintaining a stable genome. Other mouse models generated probe the importance of components of the p53 pathway. For example, loss of Mdm2 or Mdm4 (genes that encode p53 inhibitors) results in embryonic lethality that is completely rescued by concomitant loss of p53. These studies indicate the importance of regulating p53 activity. We have made conditional loss-of-function allele of Mdm2 and Mdm4 to access the role of p53 in different cell types as a function of proliferation. Finally, we are studying individuals with Li-Fraumeni Syndrome, most of whom inherit a p53-missense mutation. Various factors including, modifiers of the p53 pathway alter the onset of tumorigenesis in these individuals.
View a complete list of Dr. Lozano's publications.
Visit Dr. Lozano's Lab website.
Follow Dr. Lozano on Twitter: @drgglozano
View Dr. Lozano's publication highlights as reflected in Elsevier's Scopus database.
Education & Training
Degree-Granting Education
| 1986 | Rutgers University and the University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, US, Biochemistry, Ph.D |
| 1979 | University of Texas Rio Grande Valley (formerly Pan American University), Edinburg, Texas, US, Biology/Mathematics, B.S |
Postgraduate Training
| 1985-1987 | Research Fellowship, Molecular Biology, Dr. Arnold J. Levine, Princeton University, Princeton, New Jersey |
Experience & Service
Administrative Appointments/Responsibilities
Co-Leader, Department of Cancer Center Support Grant, Cancer Genetics and Epigenetics Program, The University of Texas MD Anderson Cancer Center, 2013 - Present
Other Professional Positions
Member, Stand Up To Cancer Health Disparities Committee, Los Angeles, CA, 2025 - Present
Chair, Texas Academy of Medicine, Engineering, Science & Technology (TAMEST) Hill Biological Sciences Subcommittee, Austin, TX, 2025 - Present
Member, NIH Laboratory of Cancer Biology and Genetics (LCBG) Advisory Board, Bethesda, MD, 2023 - Present
Member, PMV Pharma Scientific Advisory Board, Cranbury, NJ, 2021 - Present
Member, National Human Genome Research Institute (NHGRI), Board of Scientific Counselors, Bethesda, MD, 2021 - Present
Member, Adenoid Cystic Carcinoma Research Foundation, Scientific Advisory Board, Needham, MA, 2018 - Present
Member, Scientific Advisory Committee, Stand Up To Cancer, Los Angeles, CA, 2012 - Present
Institutional Committee Activities
Member, R. Lee Clark Prize, 2025 - Present
Co-Chair, Committee on Faculty Awards, 2025 - Present
Chair, Endowed Positions and Awards Committee, 2025 - Present
Chair, Community of Science Chairs, 2025 - Present
Member, Endowed Positions and Awards Committee, 2024 - Present
Member, SPORE in Leukemia, 2023 - Present
Member, SPORE in Hepatocellular Carcinoma, 2023 - Present
Member, The James P. Allison Institute, 2022 - Present
Member, Executive Leadership Committee, 2022 - Present
Chair, Wall of Science, 2018 - Present
Member, Community of Science Chairs, 2017 - Present
Member, John H. Blaffer Lecture Series, 2007 - Present
Honors & Awards
| 2024 | Distinguished Alumni Award, The University Texas of Rio Grande Valley |
| 2022 | The John Mendelsohn Award for Faculty Leadership, The University of Texas MD Anderson Cancer Center |
| 2022 | Alexander Bodini Foundation Prize for Scientific Excellence in Medicine, American-Italian Cancer Foundation (AICF) |
| 2022 | Award for Distinguished Research in the Biomedical Sciences, Association of American Medical Colleges (AAMC) |
| 2021 | Fellow, American Association for Cancer Research Academy |
| 2020 | Member, American Academy of Arts and Sciences |
| 2020 | The 2020 Benvenuto Memorial Lecture and Award, The University of Texas MD Anderson Cancer Center |
| 2019 | Jack and Beverly Randall Prize for Excellence in Cancer Research, The University of Texas MD Anderson Cancer Center |
| 2018 | Endowed Hubert L. Olive Stringer Distinguished Chair in Oncology in Honor of Sue Gribble Stringer, The University of Texas MD Anderson Cancer Center |
| 2018 | E.E. Just Award, The American Society for Cell Biology |
| 2018 | President’s Leadership Award for Advancing Women and Minority Faculty, The University of Texas MD Anderson Cancer Center |
| 2018 | The 2018 Charles A. LeMaistre, MD Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center |
| 2017 | Hall of Fame, Greater Houston Women's Chamber of Commerce |
| 2017 | Member, National Academy of Sciences |
| 2015 | Paul E. Darlington Mentoring Award, The University of Texas MD Anderson UTHealth Houston Graduate School of Biomedical Sciences |
| 2014 | Member, The Academy of Medicine, Engineering and Science of Texas |
| 2014 | Barbara Bowman Distinguished Texas Geneticist Award, 41st Annual Meeting of the Texas Genetics Society |
| 2014 | Member, National Academy of Medicine |
| 2013 | Women in Science with Excellence (WISE) Award, BioHouston, Inc |
| 2013 | Women in Cancer Research Charlotte Friend Memorial Lectureship, American Association for Cancer Research |
| 2012 | Distinguished Alumnus Award, The University of Medicine and Dentistry of New Jersey Graduate School of Biomedical Sciences |
| 2011 | Minorities in Cancer Research Jane Cooke Wright Lectureship, American Association for Cancer Research |
| 2011 | Fellow, American Association for the Advancement of Science |
| 2010 | The 2010 Faculty Achievement Award in Basic Research, The University of Texas MD Anderson Cancer Center |
| 2004 | Mattie Allen Fair Endowed Research Chair, The University of Texas MD Anderson Cancer Center |
| 2000 | Anise J. Sorrell Endowed Professorship, The University of Texas MD Anderson Cancer Center |
| 1996 | Past State President's Award, The Texas Federation of Business & Professional Women's Clubs, Inc |
| 1994 | The 1994 Faculty Achievement Award in Basic Research, The University of Texas MD Anderson Cancer Center |
| 1993 | Dean's Teaching Excellence Award, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences |
| 1992 | Distinguished Alumnus Award, The University of Texas Rio Grande Valley (formerly Pan American University) |
| 1990 - 1991 | Outstanding Faculty Award, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences |
Professional Memberships
Grant & Contract Support
| Date: | 2022 - 2023 |
| Title: | Role of p53 missense mutations on tumorigenesis in vivo |
| Funding Source: | The Anna Fuller Fund |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Identifying the vulnerabilities in Mdm2 overexpressing cancer cells |
| Funding Source: | NIH/NCI |
| Role: | Unit Director |
| ID: | R50 CA251703 |
| Date: | 2020 - 2025 |
| Title: | Dissecting the source and mechanisms of IL-17-mediated modulation of pancreatic tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA237384 |
| Date: | 2019 - 2021 |
| Title: | Understanding the physiologically relevant functions of Daxx |
| Funding Source: | The Neuroendocrine Tumor Research Foundation (NETRF) |
| Role: | PI |
| ID: | Investigator Award |
| Date: | 2018 - 2023 |
| Title: | Identifying vulnerabilities in p53 mutant tumors |
| Funding Source: | Brockman Foundation |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Upgrade for Nikon Confocal: LUNV Laser Launch and DU-G |
| Funding Source: | NIH |
| Role: | PI |
| ID: | S10 12402226 |
| Date: | 2018 - 2022 |
| Title: | A somatic mutant p53 mouse model of metastatic triple negative breast cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP180313 |
| Date: | 2017 - 2021 |
| Title: | Identifying cooperating lesions of Mdm4/mutant p53 driven breast cancer and resistance mechanisms to Mdm4 inhibition |
| Funding Source: | Sister Institution Network Fund |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Defining diverse roles of p53 in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | 1 K08 CA218690-01 |
| Date: | 2017 - 2022 |
| Title: | The roles of TRIM24 in breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA214871 |
| Date: | 2016 - 2019 |
| Title: | Identifying vulnerabilities in mutant p53 driven tumorigenesis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | CPRIT RP170231 |
| Date: | 2016 - 2018 |
| Title: | p53Y220C Tumor Susceptibility |
| Funding Source: | PMV Pharma |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | (PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21 CA208463 |
| Date: | 2016 - 2018 |
| Title: | The Mechanistic Underpinnings of Pancreatic Neuroendocrine Tumors |
| Funding Source: | The Neuroendocrine Tumor Research Foundation (NETRF) |
| Role: | PI |
| Date: | 2012 - 2015 |
| Title: | The Mechanistic Underpinnings of Pancreatic Neuroendocrine Tumors |
| Funding Source: | The Caring for Carcinoid Foundation |
| Role: | PI |
| ID: | Foundation Grant |
| Date: | 2010 - 2014 |
| Title: | Trim 24: A Dual Regulator of p53 and Estrogen Receptor |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | CPRIT RP100602 |
| Date: | 2010 - 2016 |
| Title: | Training Program in Molecular Genetics of Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | T32 CA009299-34 |
| Date: | 2010 - 2013 |
| Title: | A Single Nucleotide Polymorphism in Mdm2 Regulates p53 Activity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | CPRIT RP100535 |
| Date: | 2009 - 2014 |
| Title: | Molecular and Epidemiologic Characterization of Salivary Gland Carcinomas |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | U01 DE019765-02 |
| Date: | 2006 - 2012 |
| Title: | A Mutational Model for Childhood Cancer, Core D, Nucleic Acids Isolation and DNA Analysis Facility |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | P01 CA34936-23 |
| Date: | 2006 - 2012 |
| Title: | A Mutational Model for Childhood Cancer, Project 3, Mouse Models for Li Fraumeni Syndrome |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P01 CA34936-23 |
| Date: | 2006 - 2007 |
| Title: | Mouse Models of Cell Cycle Deregulation in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01 ES011047 05 S1 |
| Date: | 2005 - 2007 |
| Title: | A Novel Member of the p53 Tumor Suppressor |
| Funding Source: | The Michael Kadoorie Foundation |
| Role: | PI |
| Date: | 2004 - 2010 |
| Title: | Training Program in Molecular Genetics of Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | T32 CA009299-31 |
| Date: | 2004 - 2009 |
| Title: | Mouse Models of Human Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | U01 CA84243-10 |
| Date: | 2002 - 2008 |
| Title: | Targeting the p53 Pathway for Reversal of Oral Premalignancy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA97007 |
| Date: | 2001 - 2006 |
| Title: | Experimental Molecular Therapeutic Approaches to Lung Cancer |
| Funding Source: | BESCT (Biology, Education, Screening, Chemo-prevention, and Treatment) Lung Cancer Program |
| Role: | Co-I |
| ID: | DAMD 17-01-1-0689-1 |
| Date: | 1999 - 2026 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA082577-23 NCE |
| Date: | 1996 - 2005 |
| Title: | A Mutational Model for Childhood Cancer, Project |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | CA34936 |
| Date: | 1996 - 2005 |
| Title: | A Mutational Model for Childhood Cancer, Core |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | CA34936 |
| Date: | 1996 - 2026 |
| Title: | Cancer Center Support Grant, Cancer Genetics and Epigenetics |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5 P30 CA016672 |
| Date: | 1996 - 2026 |
| Title: | Cancer Center Support Grant, Genetically Engineered Mouse Facility (GEMF) |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | P30 CA016672 |
| Date: | 1988 - 2027 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 2R01 CA047296-34 |
Selected Publications
Peer-Reviewed Articles
- Xiong S, Zhang Y, Zhou X, Pant V, Mirani A, Gencel-Augusto J, Chau G, You MJ, Lozano G. Dependence on Mdm2 for Mdm4 inhibition of p53 activity. Cancer Lett 621:217622, 2025. e-Pub 2025. PMID: 40081463.
- Puzio-Kuter AM, Xu L, McBrayer MK, Dominique R, Li HH, Fahr BJ, Brown AM, Wiebesiek AE, Russo BM, Mulligan CL, Yang H, Battaglia J, Robell KA, Thomas DH, Huang KS, Solovyov A, Greenbaum BD, Oliner JD, Davis TW, Dumble ML, Johnson ML, Xiong S, Yang P, Lozano G, Fellous MM, Vu BT, Schram AM, Levine AJ, Poyurovsky MV. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discov 15(6):1159-1179, 2025. e-Pub 2025. PMID: 39945593.
- Lozano G, Prives C, Sabapathy K. Mutant p53 Gain of Function: Why Many See It, Why Some Do Not. Cancer Discov 15(6):1099-1104, 2025. e-Pub 2025. PMID: 40287981.
- Castro-Pando S, Howell RM, Li L, Mascaro M, Faraoni EY, Le Roux O, Romanin D, Tahan V, Riquelme E, Zhang Y, Kolls JK, Allison JP, Lozano G, Moghaddam SJ, McAllister F. Pancreatic epithelial IL-17/IL-17RA signaling drives B7-H4 expression to promote tumorigenesis. Cancer Immunol Res 12(9):1170-1183, 2024. e-Pub 2024. PMID: 38842383.
- Ghazi PC, O'Toole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, Bogdan M, Smith BD, Lozano G, Flynn DL, Snyder EL, Kinsey CG, McMahon M. Inhibition of ULK1/2 and KRAS(G12C) controls tumor growth in preclinical models of lung cancer. Elife 13, 2024. e-Pub 2024. PMID: 39213022.
- McDaniel JM, Morrissey RL, Dibra D, Patel LR, Xiong S, Zhang Y, Chau GP, Su X, Qi Y, El-Naggar AK, Lozano G. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun 4(8):1991-2007, 2024. e-Pub 2024. PMID: 38994678.
- Dibra, D, Xiong, S, Moyer, SM, El-Naggar, AK, Qi, Y, Su, X, Kong, EK, Korkut, A, Lozano, G. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Science Advances 10(7), 2024. e-Pub 2024. PMID: 38354236.
- Dibra, D, Gagea Iurascu, M, Qi, Y, Chau, GP, Su, X, Lozano, G. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Research Communications 3(12):2640-2652, 2023. e-Pub 2023. PMID: 38047594.
- Sun C, Qi Y, Fowlkes N, Lazic N, Su X, Lozano G, Wasylishen AR. The histone chaperone function of Daxx is dispensable for embryonic development. Cell Death Dis 14(8):565, 2023. e-Pub 2023. PMID: 37633949.
- Dibra D, Moyer SM, El-Naggar AK, Qi Y, Su X, Lozano G. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A 120(34):e2308807120, 2023. e-Pub 2023. PMID: 37579145.
- Chachad D, Patel LR, Recio CV, Pourebrahim R, Whitley EM, Wang W, Su X, Xu A, Lee DF, Lozano G. Unique transcriptional profiles underlie osteosarcomagenesis driven by different p53 mutants. Cancer Res 83(14):2297-2311, 2023. e-Pub 2023. PMID: 37205631.
- Gencel-Augusto J, Su X, Qi Y, Whitley EM, Pant V, Xiong S, Shah V, Lin J, Perez E, Fiorotto ML, Mahmud I, Jain AK, Lorenzi PL, Navin NE, Richie ER, Lozano G. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov 13(5):OF1-OF20, 2023. e-Pub 2023. PMID: 37067911.
- Yu X, Zhang Y, Xiong S, McDaniel JM, Sun C, Chau GP, Gencel-Augusto J, Chachad D, Morrissey RL, Rao X, Wang J, Lozano G. Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling. Proc Natl Acad Sci U S A 119(45):e2210618119, 2022. e-Pub 2022. PMID: 36322759.
- Ding J, Li X, Khan S, Zhang C, Gao F, Sen S, Wasylishen AR, Zhao Y, Lozano G, Koul D, Alfred Yung WK. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro Oncol 24(10):1712-1725, 2022. e-Pub 2022. PMID: 35474131.
- Mejía-Hernández JO, Keam SP, Saleh R, Muntz F, Fox SB, Byrne D, Kogan A, Pang L, Huynh J, Litchfield C, Caramia F, Lozano G, He H, You JM, Sandhu S, Williams SG, Haupt Y, Haupt S. Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss. Cell Death Dis 13(9):777, 2022. e-Pub 2022. PMID: 36075907.
- Sun C, Estrella JS, Whitley EM, Chau GP, Lozano G, Wasylishen AR. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. Dis Model Mech 15(8), 2022. e-Pub 2022. PMID: 35976056.
- Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernández C, Lorenzini D, Hoang A, Lu W, Soto LMS, Wistuba II, Xu M, Song X, Shepherd PDA, Navone NM, Tidwell RSS, Lozano G, Logothetis C, Zhang J, Long JP, Estecio MR, Tzelepi V, Aparicio AM. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35805010.
- Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, Su X, Whitley EM, El-Naggar AK, Lozano G. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Res 82(10):1926-1936, 2022. e-Pub 2022. PMID: 35320355.
- Pant V, Aryal NK, Xiong S, Chau GP, Fowlkes NW, Lozano G. Alterations of the MDM2 C-terminus differentially impact its function in vivo. Cancer Res 82(7):1313-1320, 2022. e-Pub 2022. PMID: 35078816.
- Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A blood-based polyamine signature associated with MEN1 duodenopancreatic neuroendocrine tumor progression. J Clin Endocrinol Metab 106(12):e4969-e4980, 2021. e-Pub 2021. PMID: 34318891.
- Shah VV, Duncan AD, Jiang S, Stratton SA, Allton KL, Yam C, Jain A, Krause PM, Lu Y, Cai S, Tu Y, Zhou X, Zhang X, Jiang Y, Carroll CL, Kang Z, Liu B, Shen J, Gagea M, Manu SM, Huo L, Gilcrease M, Powell RT, Guo L, Stephan C, Davies PJ, Parker-Thornburg J, Lozano G, Behringer RR, Piwnica-Worms H, Chang JT, Moulder SL, Barton MC. Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer. Nat Commun 12(1):5389, 2021. e-Pub 2021. PMID: 34508101.
- Perez EA, Jaffee EM, Whyte J, Boyce CA, Carpten JD, Lozano G, Williams RM, Winkfield KM, Bernstein D, Poblete S. Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study. JMIR Cancer 7(3):e25621, 2021. e-Pub 2021. PMID: 34554099.
- Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylishen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov 11(8):2094-2111, 2021. e-Pub 2021. PMID: 33839689.
- Jeffers JR, Pinto EM, Rehg JE, Clay MR, Wang J, Neale G, Heath RJ, Lozano G, Lalli E, Figueiredo BC, Pappo AS, Rodriguez-Galindo C, Chen W, Pounds S, Ribeiro RC, Zambetti GP. The Common Germline TP53-R337H Mutation is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model. Cancer Res 81(9):2442-2456, 2021. e-Pub 2021. PMID: 33637564.
- Zhou X, Beilter A, Xu Z, Gao R, Xiong S, Paulucci-Holthauzen A, Lozano G, de Crombrugghe B, Gorlick R. Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis 12(6):521, 2021. e-Pub 2021. PMID: 34021120.
- Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell 39(21):00108-2, 2021. e-Pub 2021. PMID: 33667384.
- Moyer SM, Wasylishen AR, Qi Y, Fowlkes N, Su X, Lozano G. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci U S A 117(38):23663-23673, 2020. e-Pub 2020. PMID: 32900967.
- Wasylishen AR, Sun C, Moyer SM, Qi Y, Chau GP, Aryal NK, McAllister F, Kim MP, Barton MC, Estrella JS, Su X, Lozano G. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci Adv 6(32):eaba8415, 2020. e-Pub 2020. PMID: 32821827.
- Wasylishen AR, Sun C, Chau GP, Qi Y, Su X, Kim MP, Estrella JS, Lozano G. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A 117(12):6622-6629, 2020. e-Pub 2020. PMID: 32156729.
- Haupt S, Caramia F, Herschtal A, Soussi T, Lozano G, Chen H, Liang H, Speed TP, Haupt Y. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nat Commun 10(1):5385, 2019. e-Pub 2019. PMID: 31772231.
- Pant V, Xiong S, Wasylishen AR, Larsson CA, Aryal NK, Chau G, Tailor RC, Lozano G. Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proc Natl Acad Sci U S A 116(35):17429-17437, 2019. e-Pub 2019. PMID: 31409715.
- Treisman DM, Li Y, Pierce BR, Li C, Chervenak AP, Tomasek GJ, Lozano G, Zheng X, Kool M, Zhu Y. Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. Neurooncol Adv 1(1):vdz027, 2019. e-Pub 2019. PMID: 31763624.
- Aryal NK, Pant V, Wasylishen AR, Rimel B, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G. Dicer1 phospho-mimetic promotes tumor progression and dissemination. Cancer Res 26(10):2662-2668, 2019. e-Pub 2019. PMID: 30914430.
- Aryal NK, Pant V, Wasylishen AR, Parker-Thornburg J, Baseler L, El-Naggar AK, Liu B, Kalia A, Lozano G, Arur S. Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo. Proc Natl Acad Sci U S A 116(3):960-969, 2019. e-Pub 2019. PMID: 30593561.
- Wasylishen AR, Estrella JS, Pant V, Chau GP, Lozano G. Daxx Functions Are p53-Independent In Vivo. Mol Cancer Res 16(10):1523-1529, 2018. e-Pub 2018. PMID: 29903771.
- Aryal NK, Wasylishen AR, Lozano G. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo. Cell Death Dis 9(11):1099, 2018. e-Pub 2018. PMID: 30368519.
- Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun 9(1):3953, 2018. e-Pub 2018. PMID: 30262850.
- Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Sanchez EV, Wang TC, Bailey JM, McAllister F. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155(1):210-223, 2018. e-Pub 2018. PMID: 29604293.
- Larsson CA, Moyer SM, Liu B, Michel KA, Pant V, Yang P, Wong J, El-Naggar AK, Krahe R, Lozano G. Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration. Proc Natl Acad Sci U S A 115(9):2198-2203, 2018. e-Pub 2018. PMID: 29440484.
- Dibra D, Xia X, Gagea M, Lozano G, Li S. A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53. PLoS One 13(3):e0193485, 2018. e-Pub 2018. PMID: 29494633.
- Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37(3):332-340, 2018. e-Pub 2018. PMID: 28925402.
- Aryal NK, Wasylishen AR, Pant V, Riley-Croce M, Lozano G. Loss of digestive organ expansion factor (Diexf) reveals an essential role during murine embryonic development that is independent of p53. Oncotarget 8(61):103996-104006, 2017. e-Pub 2017. PMID: 29262616.
- Liu B, Mitani Y, Rao X, Zafereo M, Zhang J, Zhang J, Futreal PA, Lozano G, El-Naggar AK. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst 109(10), 2017. e-Pub 2017. PMID: 29117356.
- Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP, McArthur MJ, Ostrowski MC, and Lozano G. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53. Genes & Dev 31(18):1847-1857, 2017. e-Pub 2017. PMID: 29021240.
- Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8(16):25837-25847, 2017. e-Pub 2017. PMID: 28460439.
- Xiong S, Pant V, Zhang Y, Aryal NK, James You M, Kusewitt D, Lozano G. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumorigenesis. J Pathol 241(4):501-510, 2017. e-Pub 2017. PMID: 27925213.
- Xie X, Lozano G, Siddik ZH. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene 35(36):4798-806, 2016. e-Pub 2016. PMID: 26876197.
- Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, Kleinerman ES, Lozano G, Li S. Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo. Clin Cancer Res 22(15):3876-83, 2016. e-Pub 2016. PMID: 26979394.
- Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in concert with an IL27 Receptor α deficiency causes spontaneous liver inflammation, fibrosis, and steatosis. Hepatology 63(3):1000-12, 2016. e-Pub 2016. PMID: 26637970.
- Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, El-Naggar AK. Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations. Clin Cancer Res 22(3):725-33, 2016. e-Pub 2016. PMID: 26631609.
- Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M. Mdm2 associates with Polycomb Repressor Complex 2 and enhances stemness promoting chromatin modifications independent of p53. Mol Cell 61(1):68-83, 2016. e-Pub 2016. PMID: 26748827.
- Tashakori M, Zhang Y, Xiong S, You MJ, Lozano G. p53 Activity Dominates that of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res 14(1):56-65, 2016. e-Pub 2016. PMID: 26527653.
- Pant V, Xiong S, Chau G, Tsai K, Shetty G, Lozano G. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene 35(44):5713-5721, 2016. e-Pub 2016. PMID: 27065327.
- Riley MF, You MJ, Multani AS, Lozano G. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis resulting in B-cell lymphoma. Oncogene 35(2):358-365, 2016. e-Pub 2016. PMID: 25915849.
- Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, Urbani A, Xiong S, Soddu S, Masetti R, Lozano G, Pontecorvi A, Moretti F. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene 34(2):228-240, 2016. e-Pub 2016. PMID: 25961923.
- Charni M, Molchadsky A, Goldstein I, Solomon H, Tal P, Goldfinger N, Yang P, Porat Z, Lozano G, Rotter V. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death Differ 23(3):509-520, 2015. e-Pub 2015. PMID: 26358154.
- Goh AM, Xue Y, Leushacke M, Li L, Wong JS, Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, Lozano G, Terzian T, Lane DP. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget 6(20):17968-80, 2015. e-Pub 2015. PMID: 26255629.
- Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523(7560):352-6, 2015. e-Pub 2015. PMID: 26009011.
- Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62(2):371-9, 2015. e-Pub 2015. PMID: 25281858.
- Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene TRIM62 (DEAR1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 234(1):108-119, 2014. e-Pub 2014. PMID: 24890125.
- Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233(4):380-391, 2014. e-Pub 2014. PMID: 24789767.
- Yokoyama M, Okada S, Nakagomi A, Moriya J, Shimizu I, Nojima A, Yoshida Y, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Fruttiger M, Lozano G, Minamino T. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Rep 7(5):1691-703, 2014. e-Pub 2014. PMID: 24857662.
- Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, Lozano G, Zhu C, Watowich SS, Ullrich SE, Sun SC. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol 15(6):562-570, 2014. e-Pub 2014. PMID: 24777531.
- Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Molecular Cancer Research 12(6):901-911, 2014. e-Pub 2014. PMID: 24598047.
- Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci USA 111(30):11145-11150, 2014. e-Pub 2014.
- Ma J, Xiong M, You M, Lozano G, Amos CI. Genome-wide association tests of inversions with application to psoriasis. Human Genetics 133(8):967-74, 2014. e-Pub 2014. PMID: 24623382.
- Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discov 3(10):1172-89, 2013. e-Pub 2013. PMID: 23838884.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development and longevity. Genes Dev 27(17):1857-1867, 2013. e-Pub 2013. PMID: 23973961.
- Chen YC, Chan JYH, Chiu YL, Liu ST, Lozano G, Wang SL, Ho CL, Huang SM. Grail as a Molecular Determinant for the Functions of the Tumor Suppressor p53 in Tumorigenesis. Cell Death Differ 20:732-743, 2013. e-Pub 2013.
- Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, Ratnayaka I, Zhong S, Goldin RD, Lozano G, McKeon FD, Tavassoli M, Fritzsche F, Huber GF, Rossle M, Moch H, Lu X. ASPPS suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci, USA 110:17969-17974, 2013. e-Pub 2013.
- Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle 12:1722-1731, 2013. e-Pub 2013.
- Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rozenfeld N, Harpaz, N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23:634-646, 2013. e-Pub 2013. PMID: 23680148.
- Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba I, Sen S, Lott ST, Killary AM. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGFbeta-driven epithelial-mesenchymal transition. Cancer Discovery 3(10):1172-1189, 2013. e-Pub 2013.
- Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53 mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21(6):793-806, 2012. e-Pub 2012. PMID: 22698404.
- Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, Gjertsen BT, Madsen L, Marine JC, Blagoev B, Kristiansen K. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ 19(8):1381-1389, 2012. e-Pub 2012.
- Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci USA 108(29):1995-2000, 2011. e-Pub 2011. PMID: 21730132.
- Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 129(6):663-673, 2011. e-Pub 2011. PMID: 21305319.
- McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi J, Pani A, Smeyne R, Johnson D, Dyer MA. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20(2):260-275, 2011. e-Pub 2011.
- Lin S, Yu L, Yang J, Liu Z, Karia B, Bishop AJ, Jackson J, Lozano G, Copland JA, Mu X, Sun B, Sun LZ. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-beta (TGF-beta). J Biol Chem 286(51):44023-44034, 2011. e-Pub 2011. PMID: 22039050.
- Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G. A Pin1/Mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20(1):79-91, 2011. e-Pub 2011.
- Williams MD, Zhang L, Elliott DD, Perrier ND, Lozano G, Clayman GL, El-Naggar. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol 42(9):1213-1220, 2011. e-Pub 2011.
- Terzian T, Dumble M, Arbab F, Thaller C, Donehower LA, Lozano G, Justice MJ, Roop DR, Box NF. Rp127a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol 224(4):540-552, 2011. e-Pub 2011.
- Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintas-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121(3):893-904, 2011. e-Pub 2011.
- Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin A, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest 121(3):851-865, 2011. e-Pub 2011.
- Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168-7175, 2011. e-Pub 2011.
- Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 7(5):606-617, 2010. e-Pub 2010. PMID: 21040902.
- Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5(5):e10813, 2010. e-Pub 2010. PMID: 20520810.
- Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 29(9):1260-1269, 2010. e-Pub 2010. PMID: 19935700.
- Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, Chen Z, Chauchereau A. E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol 30(2):524-36, 2010. e-Pub 2010. PMID: 19917728.
- Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M, Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70(23):9650-9658, 2010. e-Pub 2010. PMID: 20952507.
- Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18(3):220-230, 2010. e-Pub 2010.
- Tian L, Peng G, Parant JM, Leventaki V, Drakos I, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29:6125-6137, 2010. e-Pub 2010.
- Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock P, Lozano G, Robinson WA, Roop DR, Box NF. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23(6):781-794, 2010. e-Pub 2010.
- Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene 29(22):3287-3296, 2010. e-Pub 2010. PMID: 20305689.
- Nurieva RI, Zheng S Jin W, Chung Y, Zhang Y, Martinez GJ, Reynolds JM, Wang SL, Lin X, Sun SC, Lozano G, Dong C. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 32:670-680, 2010. e-Pub 2010. PMID: 20493730.
- Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70(18):7148-7154, 2010. e-Pub 2010. PMID: 20736370.
- Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 30(10):1789-1795, 2009. e-Pub 2009. PMID: 19635748.
- Valentin-Vega YA, Box N, Terzian T, Lozano G. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation 77(5):442-449, 2009. e-Pub 2009. PMID: 19371999.
- Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 4(4):e5401, 2009. e-Pub 2009. PMID: 19404390.
- Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68(21):8968-8975, 2008. e-Pub 2008. PMID: 18974141.
- Valentin-Vega YA, Okano H, Lozano G. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ 15(11):1772-1781, 2008. e-Pub 2008. PMID: 18636077.
- Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, Chau GP, Koch JG, Eischen CM, Lozano G. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene 27(13):1813-1820, 2008. e-Pub 2008. PMID: 17906694.
- Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22(10):1337-1344, 2008. e-Pub 2008.
- Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS ONE 3(4):e1951, 2008. e-Pub 2008. PMID: 18398474.
- Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 6(6):947-955, 2008. e-Pub 2008. PMID: 18567799.
- Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor, E, Lozano G, Zipori D, Sarig R Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PloS ONE 3:e3707, 2008. e-Pub 2008.
- Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213(4):360-368, 2007. e-Pub 2007. PMID: 17893884.
- Bu P, Evrard YA, Lozano G, Dent SY. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol 27(9):3405-3416, 2007. e-Pub 2007. PMID: 17325035.
- Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 27(15):5479-5485, 2007. e-Pub 2007.
- Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20(1):54-62, 2007. e-Pub 2007. PMID: 17143258.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 115(23):2925-2930, 2007. e-Pub 2007. PMID: 17533180.
- Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117(7):1893-1901, 2007. e-Pub 2007. PMID: 17607363.
- Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D, Jerry DJ, Blackburn AC, Peltz G, Amos CI, Lozano G. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 18(5):1432-1777, 2007. e-Pub 2007. PMID: 17557176.
- Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC. Distinct roles of mdm2 and mdm4 in red cell production. Blood 109(6):2630-2633, 2007. e-Pub 2007. PMID: 17105817.
- Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8(5):497-503, 2007. e-Pub 2007. PMID: 17396137.
- Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26(48):6896-6904, 2007. e-Pub 2007. PMID: 17486075.
- Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 38(10):1553-1562, 2007. e-Pub 2007.
- Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 103(52):19842-19847, 2006. e-Pub 2006. PMID: 17170138.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 103(9):3226-3231, 2006. e-Pub 2006. PMID: 16492743.
- Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26(1):192-198, 2006. e-Pub 2006. PMID: 16354690.
- Ayanga B, Price R, Gu X, Lozano G, Evans SC. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes, Chromosomes and Cancer 45:668-675, 2006. e-Pub 2006. PMID: 16586494.
- Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 66:9502-9508, 2006. e-Pub 2006. PMID: 17018606.
- Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res 65(2):427-431, 2005. e-Pub 2005. PMID: 15695383.
- Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, Moore DD. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol 19:1646-1653, 2005. e-Pub 2005. PMID: 15831521.
- Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36(1):63-68, 2004. e-Pub 2004. PMID: 14702042.
- Evans SC, Liang M, Amos C, Gu X, Lozano G. A novel genetic modifier of p53, mop1, results in embryonic lethality. Mamm Genome 15:415-423, 2004. e-Pub 2004. PMID: 15181534.
- Bond GL, Hu W, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602, 2004. e-Pub 2004. PMID: 15550242.
- Baggerly, K, Mitra, R, Grier, R, Medhane, D, Lozano, G, Kapoor, M. Comparison of sample-labeling techniques in DNA microarray experiments. Analytica Chimica Acta 504:117-125, 2004. e-Pub 2004.
- Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119(6):861-872, 2004. e-Pub 2004.
- Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, de Vries A, Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 23(46):7644-7650, 2004. e-Pub 2004. PMID: 15361844.
- Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, Hung MC. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res 64(24):9080-9095, 2004. e-Pub 2004. PMID: 15604276.
- Obeyesekere MN, Tecarro E, Lozano G. Model predictions of MDM2 mediated cell regulation. Cell Cycle 3(5):655-661, 2004. e-Pub 2004. PMID: 15107623.
- Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van Den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24:8884-8894, 2004. e-Pub 2004. PMID: 15456863.
- Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg WC, Kulesz-Martin M. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis 25:157-167, 2004. e-Pub 2004. PMID: 14578165.
- Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113:238-243, 2003. e-Pub 2003. PMID: 12802680.
- Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791, 2003. e-Pub 2003. PMID: 12654245.
- Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet 72:975-983, 2003. e-Pub 2003. PMID: 12610779.
- Wong SS, Lozano G, Gaff CL, Gardner RJ, Strong LC, Aittomaki K, Lindeman GJ. Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Intern Med J 33:621, 2003. e-Pub 2003. PMID: 14656244.
- Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 23:7096-7107, 2003. e-Pub 2003. PMID: 14517281.
- Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 63(24):8664-8669, 2003. e-Pub 2003. PMID: 14695178.
- Lu X, Lozano G, Donehower LA. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res 522:69-83, 2003. e-Pub 2003. PMID: 12517413.
- Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchénio T, Lozano G, Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99(23):14849-14854, 2002. e-Pub 2002. PMID: 12403821.
- Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, Lozano G, Zhang W. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 21:7100-7113, 2002. e-Pub 2002. PMID: 12370832.
- Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN. p53 and Fas ligand are required for psoralen and VA-induced apoptosis in mouse epidermal cells. Cell Death Differ 9:549-560, 2002. e-Pub 2002. PMID: 11973613.
- Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 32:145-147, 2002. e-Pub 2002. PMID: 11857803.
- Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277:19251-19254, 2002. e-Pub 2002. PMID: 11953423.
- Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29(1):92-95, 2001. e-Pub 2001. PMID: 11528400.
- Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20:4041-4049, 2001. e-Pub 2001. PMID: 11494132.
- Huang W, Wang SL, Lozano G, de Crombrugghe B. cDNA library screening using the SOS recruitment system. Biotechniques 30:94-100, 2001. e-Pub 2001. PMID: 11196326.
- Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. A DNA damage-induced p53 serine 392 kinase complex contains FACTp140, hSSRP1 and CK2. Mol Cell 7:283-292, 2001. e-Pub 2001. PMID: 11239457.
- Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan Z. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol 60:900-906, 2001. e-Pub 2001. PMID: 11641417.
- Parant J, Reinke V, Mims B, Lozano G. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene 270:277-283, 2001. e-Pub 2001. PMID: 11404026.
- El-Naggar AK, Lai S, Clayman GL, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 22:729-735, 2001. e-Pub 2001. PMID: 11323391.
- Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19ARF tumor suppressor. Genes Dev 14:2358-2365, 2000. e-Pub 2000. PMID: 10995391.
- Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174-4179, 2000. e-Pub 2000. PMID: 10760284.
- Kapoor M, Hamm R, Yan W, Taya Y, Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene 19:358-364, 2000. e-Pub 2000. PMID: 10656682.
- de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19:1691-1697, 2000. e-Pub 2000. PMID: 10763826.
- Reinke V, Bortner DM, Amelse LL, Lundgren K, Rosenberg MP, Finlay CA, Lozano G. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ 10:147-154, 1999. e-Pub 1999. PMID: 10099828.
- Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov RV, Lozano G, Oren M, Haupt Y. Critical role for serine 20 of human p53 in the negative regulation of p53 by Mdm2. Embo J 18:1805-1814, 1999. e-Pub 1999. PMID: 10202144.
- McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 188:322-328, 1999. e-Pub 1999. PMID: 10419603.
- Casau AE, Vaughan JE, Lozano G, Levine AJ. Germ cell expression of an isolated human endogenous retroviral long terminal repeat of the HERV-K/HTDV family in transgenic mice. J Virol 73:9976-9983, 1999. e-Pub 1999. PMID: 10559311.
- Hung J, Mims B, Lozano G, Strong L, Harvey C, Chen TT, Stastny V, Tomlinson G. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat 14:216-221, 1999. e-Pub 1999. PMID: 10477429.
- Evans SC, Foster CJ, El-Naggar A, Lozano G. Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor. Genomics 57:182-183, 1999. e-Pub 1999. PMID: 10191103.
- Keller D, Zeng X, Li X, Kapoor M, Iordanov MS, Taya Y, Lozano G, Magun B, Lu H. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced p53 activation and phosphorylation at serine 389 but not serine 15. Biochem Biophys Res Commun 261:464-471, 1999. e-Pub 1999. PMID: 10425208.
- Evans SC, Mims B, McMasters KM, Foster CJ, deAndrade M, Amos CI, Strong LC, Lozano G. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet 102:681-686, 1998. e-Pub 1998. PMID: 9703430.
- Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, Perez-Soler R. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst 90:1130-1137, 1998. e-Pub 1998. PMID: 9701362.
- Kapoor M, Montes de Oca Luna R, Liu G, Lozano G, Cummings C, Mancini M, Ouspenski I, Brinkley BR, May GS. The cenpB gene is not essential in mice. Chromosoma 107:570-576, 1998. e-Pub 1998. PMID: 9933410.
- Anaya P, Evans SC, Dai C, Lozano G, May GS. Isolation of the Aspergillus nidulans sudD gene and its human homologue. Gene 211:323-329, 1998. e-Pub 1998. PMID: 9602165.
- Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 95:2834-2837, 1998. e-Pub 1998. PMID: 9501176.
- Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and x-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 58(4):698-703, 1998. e-Pub 1998. PMID: 9485023.
- Reinke V, Lozano G. Differential activation of p53 targets in UV-treated cells that undergo both apoptosis and growth arrest. Radiat Res 148(2):115-122, 1997. e-Pub 1997. PMID: 9254729.
- Reinke V, Lozano G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15(13):1527-1534, 1997. e-Pub 1997. PMID: 9380404.
- Montes de Oca Luna R, Amelse LA, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet 16:336-337, 1997. e-Pub 1997. PMID: 9241268.
- Ruifrok AC, Mason KA, Lozano G, Thames HD. Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor Beta 1-3 and their receptors in mouse Jejunum after radiation treatment. Radiat Res 147(1):1-12, 1997. e-Pub 1997. PMID: 8989363.
- Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15(23):2767-2772, 1997. e-Pub 1997. PMID: 9419967.
- Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. Targeted expression of mdm2 uncouples S-phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11(6):714-725, 1997. e-Pub 1997. PMID: 9087426.
- de Oca Luna RM, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, Colman MS, Finlay CA, Lozano G. The organization and expression of the mdm2 gene. Genomics 33(3):352-357, 1996. e-Pub 1996. PMID: 8660994.
- Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene 13:1315-1322, 1996. e-Pub 1996. PMID: 8808706.
- McMasters KM, Montes de Oca Luna R, Peña JR, Lozano G. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 13(8):1731-1736, 1996. e-Pub 1996. PMID: 8895519.
- Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 271(46):29380-29385, 1996. e-Pub 1996. PMID: 8910602.
- Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378(6553):203-206, 1995. e-Pub 1995. PMID: 7477326.
- Ghebranious NR, Knoll BJ, Yavorkovsky L, Ilic Z, Papaconstantinou J, Lozano G, Sell S. Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafeto protein gene regulatory region in transgenic mice. Mol Reprod Dev 42:1-6, 1995. e-Pub 1995. PMID: 8562043.
- Ghebranious N, Knoll BJ, Wu H, Lozano G, Sell S. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol Carcin 13:104-111, 1995. e-Pub 1995. PMID: 7605578.
- de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP, et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase-C isoforms. Role for p53 independent induction of gadd-45 in initiating death. J Clin Invest 96:1874-1886, 1995. e-Pub 1995. PMID: 7560079.
- Deffie A, Hao M, Montes de Oca Luna R, Hulboy DL, Lozano G. Cyclin E restores p53 activity in contact-inhibited cells. Mol Cell Biol 15(7):3926-3933, 1995. e-Pub 1995. PMID: 7791798.
- Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 14(10):6858-6867, 1994. e-Pub 1994. PMID: 7935403.
- Hulboy DL, Lozano G. Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ 5(10):1023-1031, 1994. e-Pub 1994. PMID: 7848903.
- Wu H, Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem 269(31):20067-20074, 1994. e-Pub 1994. PMID: 8051093.
- Hao M, Finlay CA, Lozano G. A functionally inactive p53 Li-Fraumeni syndrome mutant. Oncogene 8(2):299-306, 1993. e-Pub 1993. PMID: 8426739.
- Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T-antigen abrogates p53-mediated transcriptional activity. Oncogene 8:2805-2812, 1993. e-Pub 1993. PMID: 8378089.
- Deffie A, Wu H, Reinke V, Lozano G. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13(6):3415-3423, 1993. e-Pub 1993. PMID: 7684498.
- Raycroft L, Lozano G. A convenient cloning vector containing the GAL4 DNA-binding domain. Gene 118(1):143-144, 1992. e-Pub 1992. PMID: 1511878.
- Goldberg H, Helaakoski T, Garrett LA, Karsenty G, Pellegrino A, Lozano G, Maity S, de Crombrugghe B. Tissue-specific expression of the mouse alpha 2(I) collagen promoter. studies in transgenic mice and in tissue culture cells. J Biol Chem 267(27):19622-19630, 1992. e-Pub 1992. PMID: 1527081.
- Raycroft L, Schmidt JR, Yoas K, Hao MM, Lozano G. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol 11(12):6067-6074, 1991. e-Pub 1991. PMID: 1944276.
- Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res 19(17):4747-4752, 1991. e-Pub 1991. PMID: 1891364.
- Garofalo S, Vuorio E, Metsaranta M, Rosati R, Toman D, Vaughan J, Lozano G, Mayne R, Ellard J, Horton W. Reduced amounts of cartilage collagen fibrils and growth plate anomalies in transgenic mice harboring a glycine to cysteine mutation in the mouse pro alpha 1 (II) collagene gene. Proc Natl Acad Sci USA 88(21):9648-9652, 1991. e-Pub 1991. PMID: 1946380.
- Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 4(1):3-9, 1991. e-Pub 1991. PMID: 1848986.
- Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249(4972):1049-1051, 1990. e-Pub 1990. PMID: 2144364.
- De Crombrugghe B, Karsenty G, Maity S, Vuorio T, Rossi P, Ruteshouser EC, McKinney SH, Lozano G. Transcriptional mechanisms controlling types I and III collagen genes. Ann N Y Acad Sci 580:88-96, 1990. e-Pub 1990. PMID: 2337308.
- Marks J, Lin J, Miller D, Lozano G, Herbert J, Levine AJ. The expression of viral and cellular genes in papillomas of the choroid plexus induced in transgenic mice. Prog Clin Biol Res 284:163-186, 1988. e-Pub 1988. PMID: 2851142.
- McCormick D, van der Rest M, Goodship J, Lozano G, Olsen, BR. Structure of the glycosaminoglycan domain in the type IX collagen-proteoglycan. Proc Natl Acad Sci USA 84:4044-4048, 1987. e-Pub 1987. PMID: 3473493.
- Van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. The relationship between Simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol 61:2029-2032, 1987. e-Pub 1987. PMID: 3033329.
- Yagaloff KA, Lozano G, van Dyke T, Levine AJ, Hartig PR. Serotonin 5-HT1C receptors are exposed at high density on choroid plexus tumors from transgenic mice. Brain Res 385:389-394, 1986. e-Pub 1986. PMID: 3022874.
- Ninomiya Y, van der Rest M, Mayne R, Lozano G, Olsen BR. Construction and characterization of cDNA encoding the alpha 2 chain of chicken type IX collagen. Biochemistry 24:4223-4229, 1985. e-Pub 1985. PMID: 2996593.
- Lozano G, Ninomiya Y, Thompson H, Olsen BR. A distinct class of vertebrate collagen genes encodes chicken type IX collagen polypeptides. Proc Natl Acad Sci USA 82:4050-4054, 1985. e-Pub 1985. PMID: 3858862.
- Lozano G, Helle O, Muller PK. Procollagen alpha 2(I) mRNA in dermatosparactic fibroblasts: Evidence for post-transcriptional regulation. EMBO 2:1223-1227, 1983. e-Pub 1983. PMID: 10872312.
- Schultz, TW, Lozano, G, Cajina-Quezada, M. Histochemical analysis of the goblet cell matrix in the larval midgut of Manduca sexta. Transactions of the American Microscopal Society 100:204-209, 1981. e-Pub 1981.
- Vogeli G, Avvedimento VE, Sullivan M, Maizel JV, Lozano G, Adams SL, Pastan I, de Crombrugghe B. Isolation and characterization of genomic DNA coding for alpha 2 type I collagen. Nucleic Acids Res 8:1823-1837, 1980. e-Pub 1980. PMID: 7433131.
Invited Articles
- Gencel-Augusto J, Lozano G. Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect. Cancer Res 85(11):1955-1956, 2025. e-Pub 2025. PMID: 40452346.
- Pant V, Sun C, Lozano G. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death Differ 30(4):897-905, 2023. e-Pub 2023. PMID: 36755072.
- Morrissey RL, Thompson AM, Lozano G. Is loss of p53 a driver of ductal carcinoma in situ progression?. Br J Cancer 127(10):1744-1754, 2022. e-Pub 2022. PMID: 35764786.
- Barton MC, Lozano G. p53 Activation Paradoxically Causes Liver Cancer. Cancer Res 82(16):2824-2825, 2022. e-Pub 2022. PMID: 35971677.
- Gencel-Augusto J, Lozano G. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev 34(17-18):1128-1146, 2020. e-Pub 2020. PMID: 32873579.
- Lozano G. Restoring p53 in cancer: the promises and the challenges. J Mol Cell Biol 11(7):615-619, 2019. e-Pub 2019. PMID: 31283825.
- Lozano G. One step at a time. Mol Biol Cell 29(22):2614-2615, 2018. e-Pub 2018. PMID: 30376433.
- Ortiz GJ, Lozano G. SNPing away at mutant p53 activities. Genes Dev 32(3-4):195-196, 2018. e-Pub 2018. PMID: 29491132.
- Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 25(1):161-168, 2018. e-Pub 2018. PMID: 29099488.
- Jackson JG, Lozano G. TNBC invasion: downstream of STAT3. Oncotarget 8(13):20517-20518, 2017. e-Pub 2017. PMID: 28199968.
- Zhang Y, Lozano G. p53: multiple facets of a rubik’s cube. Cancer Biol 1:185-201, 2017. e-Pub 2017. PMID: 30775651.
- Moyer SM, Larsson CA, Lozano G. Mdm proteins: critical regulators of embryogenesis and homeostasis. J Mol Cell Biol 15(9):16-25, 2017. e-Pub 2017. PMID: 28093454.
- Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Front Oncol 5:249, 2015. e-Pub 2015. PMID: 26618142.
- Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: A rheostat of cancer risk. Hum Mutat 35(6):728-737, 2014. e-Pub 2014. PMID: 24488925.
- Pant V, Lozano G. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget 5:1149-1156, 2014. e-Pub 2014.
- Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 28(16):1739-1751, 2014. e-Pub 2014.
- Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Oliver M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death and Differentiation 19:180-183, 2013. e-Pub 2013.
- Li Q, Lozano G. Molecular pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy. Clin Cancer Res 19(1):34-41, 2013. e-Pub 2013.
- Jackson JG, Lozano G. Che-ating death: Che1/AATF protects from p53 mediated apoptosis. EMBO J 31(20):3951-3953, 2012. e-Pub 2012. PMID: 22960635.
- Flores ER, Lozano G. The p53 family grows old. Genes Dev 26(18):1997-2000, 2012. e-Pub 2012. PMID: 22987633.
- Xiong S, Parker-Thornburg J, Lozano G. Developing genetically engineered mouse models to study tumor suppression. Curr Protoc Mouse Biol 2(1):9-24, 2012. e-Pub 2012. PMID: 22582146.
- Jackson J, Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene:doi:10. 1038/onc. 610, 2012. e-Pub 2012.
- Pant V, Quintás-Cardama A, Lozano G. The pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood 120(26):5118-5127, 2012. e-Pub 2012. PMID: 23018641.
- Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report. Clinical Cancer Research 18:S1-100, 2012. e-Pub 2012.
- Riley MF, Lozano G. The many faces of MDM2 binding partners. Genes Cancer 3(3-4):226-239, 2012. e-Pub 2012. PMID: 23150756.
- Abbas HA, Pant V, Lozano, G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle 10(19):3257-3262, 2011. e-Pub 2011.
- Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathology 223(2):127-136, 2011. e-Pub 2011. PMID: 20957626.
- Lin PP, Wang Y, Lozano G. Mesenchymal stem cells and the origin of Ewing's sarcoma. Sarcoma, 2010. e-Pub 2010. PMID: 20953407.
- Lozano G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2(4):a001115, 2010. e-Pub 2010. PMID: 20452944.
- Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17(1):93-102, 2010. e-Pub 2010. PMID: 19498444.
- Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcoma. J Pathology 222(2):124-128, 2010. e-Pub 2010. PMID: 20801751.
- Terzian TT, Lozano G. Building p53. Genes & Development 24(20):2229-2232, 2010. e-Pub 2010.
- Eischen CM, Lozano G. p53 and MDM2: antagonists or partners in crime?. Cancer Cell 15(3):161-162, 2009. e-Pub 2009. PMID: 19249672.
- Donehower L, Lozano G. Twenty years studying p53 functions in genetically engineered mice. Nature Reviews Cancer 9(11):831-841, 2009. e-Pub 2009.
- Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 26:2177-2184, 2007. e-Pub 2007.
- Lozano G, Behringer RR. New mouse models of cancer: Single-cell knockouts. Proc Natl Acad Sci USA 104(11):4245-4246, 2007. e-Pub 2007. PMID: 17360508.
- Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 17(1):66-70, 2007. e-Pub 2007. PMID: 17208429.
- Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13:927-934, 2006. e-Pub 2006. PMID: 16543935.
- Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol 16(3):225-234, 2006. e-Pub 2006. PMID: 16697215.
- Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 4(7):41-43, 2005. e-Pub 2005. PMID: 15917654.
- Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and RB. Cancer Cell 8(1):3-4, 2005. e-Pub 2005. PMID: 16023592.
- Liu G, Lozano G. p21 stability: Linking chaperones to a cell cycle checkpoint. Cancer Cell 7(2):113-114, 2005. e-Pub 2005. PMID: 15710322.
- Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 228(1-2):21-27, 2005. e-Pub 2005. PMID: 15927364.
- Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway?. J Pathol 205(2):206-220, 2005. e-Pub 2005. PMID: 15643668.
- Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331:834-842, 2005. e-Pub 2005.
- Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 1:993-1000, 2003. e-Pub 2003. PMID: 14707282.
- Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat 21:321-326, 2003. e-Pub 2003. PMID: 12619119.
- Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature 404:24-25, 2000. e-Pub 2000. PMID: 10716425.
- Lozano G, Liu G. Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol 8(5):337-344, 1999. e-Pub 1999. PMID: 10101799.
- Lozano G, Montes de Oca Luna R. MDM2 function. Biochim Biophys Acta 1377:M55-M59, 1998. e-Pub 1998. PMID: 9606977.
- Evans SC, Lozano G. The Li-Fraumeni syndrome: An inherited susceptibility to cancer. Mol Med Today 3(9):390-395, 1997. e-Pub 1997. PMID: 9302689.
- Lozano G. Signals regulating p53- and Rb- mediated negative cell growth. The Cancer Bulletin 47:158-162, 1995. e-Pub 1995.
- Lozano, G, Hulboy, DL. Transcriptional regulation by tumor suppressor genes. Methods: A Companion to Methods in Enzymology 8:215-224, 1995. e-Pub 1995.
- Lozano G, Hansen MF, Strong LC. Functional characterization of inherited p53 mutations. The Cancer Bulletin 46:247-164, 1994. e-Pub 1994.
- Lozano G. A transgenic mouse model for studying tumor development. The Cancer Bulletin 40:287-291, 1988. e-Pub 1988.
Book Chapters
- Lozano G. The Enigma of p53. In: Cold Spring Harb Symp Quant Biol, 2016.
- Tonnessen-Murray CA, Lozano G, Jackson JG. The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence. In: Cold Spring Harb Perspect Med. Cold Spring Harbor Press, 173-186, 2016.
- Wasylishen A, Lozano G. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. In: The p53 Protein: From Cell Regulation to Cancer. Cold Spring Harbor Press, 331-350, 2016.
- Terzian T, Lozano G. Mutant p53-Driven Tumorigenesis. In: p53 in the Clinics. Springer, 77-93, 2013.
- Post SM, Quintas-Cardama A, Lozano G. Regulation of p53 Activity and Associated Checkpoint Controls. In: Checkpoint Controls and Targets in Cancer Therapy. 9. Humana Press, 1260-1269, 2010.
- Lozano G. In: Mouse Models of p53 Functions. 4. Cold Spring Harbor Perspectives, 001115, 2010.
- Chandler DS Lozano G. Metastasis. In: Mouse Models of Human Cancer. Wiley Inc, 307-320, 2004.
- Lozano G. p53. In: Wiley Encyclopedia of Molecular Medicine. John Wiley & Sons, Inc, 2365-2366, 2002.
- Lozano G. MDM2. In: Wiley Encyclopedia of Molecular Medicine. John Wiley & Sons, Inc, 2026-2028, 2002.
- Marks J, Lin J, Miller D, Lozano G, Herbert J, Levine AJ. The expression of viral and cellular genes in papillomas of the choroid plexus induced in transgenic mice. In: Cellular Factors in Development and Differentiation: Embryos, Teratocarcinomas and Differentiated Tissues. Alan R. Liss, Inc, 163-186, 1988.
- Van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. Relationship between tumor formation and SV40 T antigen expression in transgenic mice containing the SV40 early region genes. In: Gene Transfer Vectors for Mammalian Cells. Cold Spring Harbor Laboratory, 115-118, 1987.
- Lozano G, Ninomiya Y, Olsen BR. The structure of short chain collagen genes. In: Progress in Clinical and Biological Research: Progress in Developmental Biology, Part B. Alan R. Liss, Inc, 397-400, 1985.
- Olsen BR, Nimomiya Y, Konomi H, Lozano G, Vasios G, Seyer J, Eikenberry J. A novel class of collagen genes in vertebrates: Types IX collagen. In: Basement Membranes. Elsevier Science Publishers, 119-130, 1985.
- Olsen BR, Ninomiya Y, Lozano G, Konomi H, Gordon M, Green G, Parsons J, Seyer J, Thompson H, Vasios G. Short chain collagen genes and their expression in cartilage. In: The Biology, Chemistry and Pathology of Collagen. Ann. NY Acad. Sci, 141-153, 1985.
Books (edited and written)
- Lozano G, Levine AJ. The p53 Protein: From Cell Regulation to Cancer. Cold Spring Harbor Press, 2016.
Patient Reviews
CV information above last modified August 28, 2025